Home › NDC Lookup › Ingredients › Carboxymethylcellulose Sodium › 00023-9205-15
REFRESH LIQUIGEL Carboxymethylcellulose sodium 10 mg/mL Gel — NDC 00023-9205-15 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

REFRESH LIQUIGEL Carboxymethylcellulose sodium 10 mg/mL Gel — NDC 0023-9205-15 (Billing 00023-9205-15)

by Allergan, Inc. · 1 BOTTLE, DROPPER in 1 CARTON / 15 mL in 1 BOTTLE, DROPPER

This is a package of REFRESH LIQUIGEL Carboxymethylcellulose sodium 10 mg/mL Gel from Allergan, Inc., marketed since Oct 2001 and currently FDA-listed; retail pharmacies pay about $0.5781 per mL (NADAC). It is this product's only package size.

NDC 00023-9205-15
🏷️ FDA NDC (as labeled) 0023-9205-15 billing pads the labeler segment with a zero
OTC On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Sep 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0023-9205-15 alone.

Record
FDA NDC Directory package listing · Human OTC drug
Code segments
0023 labeler · 9205 product · 15 package
Package marketed since
Oct 4, 2001
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 0023920515 4
Medicaid fills, this package
10,130 prescriptions in the last four reported quarters
FDA record last changed
Sep 24, 2026
⚠️
Other active recalls for Carboxymethylcellulose Sodium (different manufacturers) — 6 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Aug 20, 2026 — Lack of Assurance of Sterility (Sterling Pharmaceutical Services LLC) · FDA recall D-0860-2026
Class II · Aug 20, 2026 — Lack of Assurance of Sterility (Sterling Pharmaceutical Services LLC) · FDA recall D-0863-2026
Class II · Aug 20, 2026 — Lack of Assurance of Sterility (Sterling Pharmaceutical Services LLC) · FDA recall D-0855-2026
Class II · Aug 20, 2026 — Lack of Assurance of Sterility (Sterling Pharmaceutical Services LLC) · FDA recall D-0858-2026
Class II · Aug 20, 2026 — Lack of Assurance of Sterility (Sterling Pharmaceutical Services LLC) · FDA recall D-0857-2026
Class II · Apr 23, 2025 — cGMP deviations and lack of assurance of sterility. (BRS Analytical Services, LLC) · FDA recall D-0406-2025
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0023-9205-15
Product NDC 0023-9205
11-digit billing NDC 00023920515
NCPDP billing unit ML — per mL (volume)
RxCUI 579907
UNII K679OBS311
Application # M018
SPL Set ID 4b8b2f6a-4b89-446c-9e5b-9b83c453a01d
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2001-10-04
Route OPHTHALMIC
Dosage form GEL
Substance CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 008640
GCN 37380
HICL code 003843
Ingredient (HICL) Carboxymethylcellulose Sodium
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6T
Therapeutic class — specific (HIC3) Artificial Tears
AHFS code 52:92.00.00
AHFS class Eent Drugs, Miscellaneous
FDB label name REFRESH LIQUIGEL 1% EYE DROP
FDB brand name Refresh Liquigel
Legend status O — Over-the-counter (OTC) drug or device
Quick answers
  • GSN (GCN sequence number): 008640
  • GCN: 37380
  • HICL (First Databank): 003843
  • AHFS class code: 52:92.00.00
  • RxCUI (RxNorm): 579907
Why two NDCs? The FDA registers this code as 0023-9205-15 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00023-9205-15. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name REFRESH LIQUIGEL 1% EYE DROP Ingredient Carboxymethylcellulose Sodium
🧪 What is this product?

Refresh Liquigel is an over-the-counter eye gel containing carboxymethylcellulose sodium, a substance typically used to lubricate and protect the eye surface. This product is applied directly to the eye and functions as an artificial tear replacement. Carboxymethylcellulose sodium is commonly found in eye drops and gels designed to help relieve dryness and irritation by coating the eye and slowing tear evaporation.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.578 $8.67 / 15 ml
Medicaid paysCMS SDUD · 12 mo $1.09 $16.28 / 15 ml
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per mL) — tap or hover for the price & month
Dec 2025 Feb 2026 Apr 2026 Aug 2026 $0.626 $0.578
Flat over the last 8 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00023-9205-15 You're viewing this Main listing 1 BOTTLE, DROPPER in 1 CARTON / 15 mL in 1 BOTTLE, DROPPER 2001-10-04 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Refresh Liquigel 10 mg/mLthis 00023-9205-15 Allergan, 1 bottle $0.578 — Availability likely —
Refresh Celluvisc 10 mg/mL 00023-4554-05 Allergan, 5 vials — — FDA listed —
carboxymethylcellulose sodium 10 mg/mL 50268-0065-30 AvPAK 30 vials — — FDA listed —
TheraTears 10 mg/mL 58790-0002-28 MEDTECH 7 pouches — — Discontinued —
TheraTears 10 mg/mL 58790-0003-30 MEDTECH 6 pouches — — FDA listed —
Dry Eye Relief 10 mg/mL 70000-0089-01 CARDINAL 1 bottle — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2001
On the market since
Oct 2001
📍
2026
Currently FDA-listed
25 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII R57ZHV85D4
    Boric acid is a weak acid derived from boron. In medicines, it typically serves as a buffer to help maintain the product's pH level and may act as a preservative in certain formulations.
  • UNII M4I0D6VV5M
    Calcium chloride is a salt compound that acts as a firming agent and source of calcium ions in medications. It's used in formulations to help maintain tablet structure, improve texture, or serve as a buffering agent.
  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII 02F3473H9O
    A mineral salt used in medications as a source of magnesium. It helps bind ingredients together, improve texture, and maintain the product's stability during storage.
  • UNII 660YQ98I10
    Potassium chloride is a mineral salt used in medicines as a buffer and to help maintain the proper pH balance and stability of the formulation during storage and use.
  • UNII 91MBZ8H3QO
    Sodium borate is an inorganic salt compound used in medicines as a buffer to help maintain a stable pH level, and sometimes as a mild preservative or cleansing agent in topical formulations.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII G538EBV4VF
    Sodium chlorite is a white crystalline salt used as a preservative and antimicrobial agent in medications. It helps prevent bacterial and fungal growth to maintain product stability during storage.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

10 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesBoric acid; calcium chloride dihydrate; magnesium chloride hexahydrate; potassium chloride; purified water; PURITE ® (stabilized oxychloro complex); sodium borate decahydrate; and sodium chloride. May contain hydrochloric acid or sodium hydroxide (to adjust pH).

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerAllergan, Inc.
FDA applicationM018 (OTC MONOGRAPH DRUG)
Labeler code00023
First marketedOct 2001
Product typeHuman Otc Drug
Portfolio188 products on file

More NDCs from Allergan, Inc. labeler code 00023

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose 📄 Stop Use and Ask a Doctor If 📄 Keep Out of Reach of Children 📄 Other Information 📄 Questions or Comments 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 31 words ▾

Uses For the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun. May be used as a protectant against further irritation.

⏱️ Dosage and Administration 12 words ▾

Directions Instill 1 or 2 drops in the affected eye(s) as needed.

⚠️ Warnings 84 words ▾

Warnings For external use only. To avoid contamination, do not touch tip of container to any surface. Replace cap after using.

If solution changes color or becomes cloudy , do not use. Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours. Keep out of reach of children.

If swallowed, get medical help or contact a Poison Control Center right away.

🧪 Active Ingredient 5 words ▾

Active ingredient Carboxymethylcellulose sodium 1%

🧪 Inactive Ingredients 35 words ▾

Inactive ingredients Boric acid; calcium chloride dihydrate; magnesium chloride hexahydrate; potassium chloride; purified water; PURITE ® (stabilized oxychloro complex); sodium borate decahydrate; and sodium chloride. May contain hydrochloric acid or sodium hydroxide (to adjust pH).

🎯 Purpose 3 words ▾

Purpose Eye lubricant

📄 Stop Use and Ask a Doctor If 33 words ▾

Stop use and ask a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours.

📄 Keep Out of Reach of Children 19 words ▾

Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

📄 Other Information 36 words ▾

Other information Use only if tape seals on top and bottom flaps are intact. Use before expiration date marked on container. Discard 90 days after opening. Store at 59°-77°F (15°-25°C). RETAIN THIS CARTON FOR FUTURE REFERENCE.

📄 Questions or Comments 13 words ▾

Questions or comments? 1.800. 6 78 . 1605 refresh eyedrops .com v2.0DFL9205 Telephone

📄 Package Label / Principal Display Panel 51 words ▾

PRINCIPAL DISPLAY PANEL NDC 0023-9205-15 Refresh Liquigel ® Lubricant Eye Gel ORIGINAL STRENGTH GEL Soothes & Comforts Dry, Irritated Eyes 0.5 fl oz (15 mL) Sterile PRINCIPAL DISPLAY PANEL NDC 0023-9205-15 Refresh Liquigel® Lubricant Eye Gel ORIGINAL STRENGTH GEL Soothes & Comforts Dry, Irritated Eyes 0.5 fl oz (15 mL) Sterile

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
10.1K
Units reimbursed last 4 qtrs
163.6K
Gross reimbursed last 4 qtrs
$177.6K
Avg / prescription
$17.53
Avg / unit
$1.0856
Latest quarter Q1 2026
2.4KRx
Medicaid pays / mL
$1.0856
gross reimbursed
vs
NADAC / mL
$0.5781
acquisition cost
=
Spread
+$0.5075
+88% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
46% FFS 54% MCO
Fee-for-service · 4,661 Rx Managed care · 5,469 Rx
State Medicaid map
Alaska: no data reported AK Maine: 645 units · 46.2 per 100k residents ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 35,640 units · 621 per 100k residents MN Wisconsin: 23,985 units · 406 per 100k residents WI Michigan: 15,975 units · 159 per 100k residents MI New York: 240 units · 1.2 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 4,605 units · 109 per 100k residents OR Nevada: 3,090 units · 96.7 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 1,620 units · 12.9 per 100k residents IL Indiana: 16,385 units · 239 per 100k residents IN Ohio: no data reported OH Pennsylvania: 13,965 units · 108 per 100k residents PA New Jersey: 1,515 units · 16.3 per 100k residents NJ Massachusetts: no data reported MA California: 9,614 units · 24.7 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: 10,295 units · 520 per 100k residents NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: 3,390 units · 38.9 per 100k residents VA Maryland: no data reported MD Connecticut: 14,445 units · 399 per 100k residents CT Rhode Island: 675 units · 61.6 per 100k residents RI Arizona: 3,400 units · 45.8 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: 1,695 units · 31.5 per 100k residents SC Delaware: 1,425 units · 138 per 100k residents DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: 405 units · 59.6 per 100k residents DC Hawaii: 600 units · 41.8 per 100k residents HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
1.2621
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Minnesota 621 /100k
2 Nebraska 520 /100k
3 Wisconsin 406 /100k
4 Connecticut 399 /100k
5 Indiana 239 /100k
6 Michigan 159 /100k
7 Delaware 138 /100k
8 Oregon 109 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Carboxymethylcellulose sodium — the ingredient across all brands.

Top reported reactions

Eye Irritation1,560
Eye Pain1,462
Macular Degeneration966
Vision Blurred885
Cataract870
Dry Eye723
Ocular Hyperaemia723

Reporter sex

13,008 reports

Serious outcomes

Hospitalization2,077
Death383
Disabling228
Life-threatening135
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 941 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
← 00023-9177-05 · Allergan, 00023-9211-03 · Allergan, →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.